eXoZymes, Inc. (EXOZ)
4.30
+0.19
(+4.62%)
USD |
NASDAQ |
Nov 06, 10:23
eXoZymes Enterprise Value : 33.58M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 33.58M |
| November 04, 2026 | 35.44M |
| November 03, 2026 | 39.52M |
| November 02, 2026 | 37.38M |
| October 30, 2026 | 33.76M |
| October 29, 2026 | 33.58M |
| October 28, 2026 | 34.65M |
| October 27, 2026 | 30.70M |
| October 26, 2026 | 30.24M |
| October 23, 2026 | 32.56M |
| October 22, 2026 | 31.63M |
| October 21, 2026 | 31.82M |
| October 20, 2026 | 33.67M |
| October 19, 2026 | 32.56M |
| October 16, 2026 | 33.39M |
| October 15, 2026 | 32.56M |
| October 14, 2026 | 38.13M |
| October 13, 2026 | 38.03M |
| October 12, 2026 | 42.30M |
| October 09, 2026 | 44.16M |
| October 08, 2026 | 44.35M |
| October 07, 2026 | 46.85M |
| October 06, 2026 | 46.67M |
| October 05, 2026 | 46.67M |
| October 02, 2026 | 48.99M |
| Date | Value |
|---|---|
| October 01, 2026 | 48.89M |
| September 30, 2026 | 49.54M |
| September 29, 2026 | 52.05M |
| September 28, 2026 | 51.12M |
| September 25, 2026 | 53.39M |
| September 24, 2026 | 54.23M |
| September 23, 2026 | 54.65M |
| September 22, 2026 | 52.88M |
| September 21, 2026 | 52.42M |
| September 18, 2026 | 55.16M |
| September 17, 2026 | 52.88M |
| September 16, 2026 | 52.61M |
| September 15, 2026 | 56.46M |
| September 14, 2026 | 53.72M |
| September 11, 2026 | 53.92M |
| September 10, 2026 | 52.70M |
| September 09, 2026 | 52.70M |
| September 08, 2026 | 54.00M |
| September 04, 2026 | 59.01M |
| September 03, 2026 | 58.55M |
| September 02, 2026 | 58.45M |
| September 01, 2026 | 55.76M |
| August 31, 2026 | 57.90M |
| August 28, 2026 | 61.96M |
| August 27, 2026 | 62.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 245.53M |
| Perspective Therapeutics, Inc. | -142.97M |
| MiMedx Group, Inc. | 357.84M |
| ABVC BioPharma, Inc. | 29.80M |
| Endonovo Therapeutics, Inc. | 7.194M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.879M |
| Total Expenses (Quarterly) | 2.879M |
| EPS Diluted (Quarterly) | -0.3324 |
| Earnings Yield | -27.95% |
| Normalized Earnings Yield | -28.27 |